These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30753317)

  • 1. Use of economic predictions to make formulary decisions.
    Picone MF; Wisniewski CS; Hayes GL
    Am J Health Syst Pharm; 2019 Feb; 76(Supplement_1):S15-S20. PubMed ID: 30753317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Outcomes Associated with a Pharmacist-Adjudicated Formulary Consult Service in a Veterans Affairs Medical Center.
    Britt RB; Hashem MG; Bryan WE; Kothapalli R; Brown JN
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1051-61. PubMed ID: 27579827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
    Hamblin S; Rumbaugh K; Miller R
    J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Few. The Effective. The Cheapest. The Waste-Free Formulary.
    Burns J
    Manag Care; 2018 Aug; 27(8):17-18. PubMed ID: 30142058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bundled Payments for Surgical Colectomy Among Medicare Enrollees: Potential Savings vs the Need for Further Reform.
    Gani F; Makary MA; Wick EC; Efron JE; Fang SH; Safar B; Hundt J; Pawlik TM
    JAMA Surg; 2016 May; 151(5):e160202. PubMed ID: 26982244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy resident involvement in prior-authorization drug request adjudication.
    Britnell SR; Brown JN; Hashem MG; Hale JC; Bryan WE; Hammond JM; Britt RB
    Am J Health Syst Pharm; 2018 Dec; 75(23 Supplement 4):S87-S93. PubMed ID: 30228166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
    Schachtner JM; Guharoy R; Medicis JJ; Newman N; Speizer R
    Am J Health Syst Pharm; 2002 Mar; 59(6):529-33. PubMed ID: 11908245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulary compliance and pharmacy labor costs associated with systematic formulary management strategy.
    Helmons PJ; Kosterink JG; Daniels CE
    Am J Health Syst Pharm; 2014 Mar; 71(5):407-15. PubMed ID: 24534596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a high-impact medication therapy subcommittee within a large academic medical center.
    Mernick F; Akrap A; MacCormack-Gagnon J
    Am J Health Syst Pharm; 2023 Jan; 80(1):e46-e52. PubMed ID: 36087114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in a program to convert i.v. to oral medications at an academic medical center.
    Hohlfelder B; Stashek C; Anger K; Szumita P
    Am J Health Syst Pharm; 2015 Dec; 72(23 Suppl 3):S145-9. PubMed ID: 26582300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program.
    Baldini CG; Culley EJ
    J Manag Care Pharm; 2011; 17(1):51-9. PubMed ID: 21204590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key design elements of shared-savings payment arrangements.
    Bailit M; Hughes C
    Issue Brief (Commonw Fund); 2011 Aug; 20():1-16. PubMed ID: 21847849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The formulary decision-making process in a US academic medical centre.
    Nash DB; Catalano ML; Wordell CJ
    Pharmacoeconomics; 1993 Jan; 3(1):22-35. PubMed ID: 10146985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive comparison of hospital formulary decisions with published oncology valuation methods.
    Lam SW; Siebenaller C; Earl M; Hill BT; Kalaycio M; Rini B; Carraway HE; Leonard M; Sekeres MA
    J Oncol Pharm Pract; 2020 Jun; 26(4):891-905. PubMed ID: 31594520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.